Sinarta powder for oral solution 1.5g/3.95g, 30 sachets — Made in Ukraine — Free Delivery

Pharmacological properties

Pharmacodynamics. The active ingredient is the salt of the amino monosaccharide glucosamine sulfate, which is found in the human body and is used together with sulfates for the biosynthesis of hyaluronic acid in the synovial fluid and glycosaminoglycans of the main substance of the articular cartilage.

The mechanism of action of glucosamine sulfate is to stimulate the synthesis of glycosaminoglycans and, accordingly, articular proteoglycans. In addition, glucosamine has anti-inflammatory properties, slows down the processes of degradation of articular cartilage mainly due to its metabolic activity, the ability to inhibit the activity of interleukin-1 (IL-1), which, on the one hand, contributes to the effect on the symptoms of osteoarthritis, and on the other hand, delay structural disorders of the joints, as evidenced by data from long-term clinical studies.

The efficacy of glucosamine sulfate against osteoarthritis is evident within 2–3 weeks from the start of treatment.

The results of clinical studies of daily continuous treatment for 3 years indicate a progressive increase in its effectiveness, taking into account the symptoms and the delay in structural damage to the joints, which is confirmed by X-ray examination.

Glucosamine sulfate has been shown to be well tolerated. No significant effect of glucosamine sulfate on the cardiovascular, respiratory, autonomic or central nervous system has been identified.

Pharmacokinetics. 90% of a dose of glucosamine sulfate is rapidly and completely absorbed from the gastrointestinal tract, passes through biological barriers and penetrates into tissues, mainly articular cartilage. Bioavailability - 26%. T½ - 68 h.

Indications

Treatment of osteoarthritis symptoms, i.e. pain and functional limitation.

Application

Adult patients and elderly patients: the contents of 1 sachet, equivalent to 1500 mg (1.5 g) of glucosamine sulfate, dissolve in a glass of water and take once a day, preferably with meals.

The course of treatment is 4–12 weeks or longer (if necessary).

According to the doctor's prescription, the treatment can be repeated 2-3 times a year with an interval of 2 months, as well as in case of a relapse of the disease.

Contraindications

Hypersensitivity to glucosamine or any of the excipients; dysfunction of the liver and kidneys in the stage of decompensation, a tendency to bleeding; powder for oral solution contains aspartame and is therefore contraindicated in patients with phenylketonuria; Sinarta should not be prescribed to patients with allergic reactions to shellfish, since the active ingredient is obtained from shellfish; During pregnancy and breastfeeding; age up to 18 years.

Side effects

From the digestive system: abdominal pain, flatulence, dyspepsia, diarrhea, constipation, nausea;

• from the nervous system: headache, drowsiness, fatigue, dizziness;
• from the immune system: allergic reactions;
• on the part of the organ of vision: visual disturbances;
• on the part of the skin and its structures: erythema, itching, rash, angioedema, urticaria, hair loss.

Special instructions

In patients with BA, the preparation should be used with caution, since such patients may be more prone to developing allergic reactions to glucosamine with a possible exacerbation of the symptoms of their disease.

The oral powder contains sorbitol. Patients with rare hereditary fructose intolerance are not recommended to use this preparation in this form of release.

1 sachet contains 6.6 mmol (151 mg) sodium. This should be taken into account in patients on a controlled sodium diet.

At the beginning of treatment for patients with diabetes mellitus, it is advisable to control the level of glucose in the blood.

Use only under medical supervision in patients with impaired liver and kidney function, with thrombophlebitis.

Use during pregnancy and lactation. There are no data on the use of the preparation during pregnancy or lactation, so the use of the preparation is contraindicated in this category of patients.

Children. Do not use in children, since the safety and efficacy of the preparation in such patients have not been established.

The ability to influence the reaction rate when driving vehicles or other mechanisms. Studies of the effect of the preparation on the ability to drive vehicles and other mechanisms have not been conducted. Be careful when driving and performing work requiring attention. In the event of drowsiness, fatigue, dizziness or visual impairment, driving and operating other mechanisms is prohibited.

Interactions

An increase in the action of coumarin anticoagulants was noted. in this regard, it is advisable for such patients to monitor the coagulation parameters. it is possible to increase the gastrointestinal absorption of tetracyclines. the preparation is compatible with npvp and gks.

Overdose

Overdose cases were not observed. based on acute and chronic toxicity studies in animals, symptoms of toxicity are unlikely to occur even at doses 200 times the therapeutic dose. however, in case of an overdose, an increase in the severity of adverse reactions is possible, so it is worthwhile to carry out symptomatic treatment aimed at restoring the water-electrolyte balance.

Storage conditions

At a temperature not exceeding 25 ° c.